Tuberculosis future or investigational therapies: Difference between revisions

	Tuberculosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Tuberculosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Children
HIV Coinfection
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Special Conditions
Drug-resistant
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Tuberculosis future or investigational therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Tuberculosis future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Tuberculosis future or investigational therapies
CDC on Tuberculosis future or investigational therapies
Tuberculosis future or investigational therapies in the news
Blogs on Tuberculosis future or investigational therapies
Directions to Hospitals Treating Tuberculosis
Risk calculators and risk factors for Tuberculosis future or investigational therapies

Revision as of 15:05, 25 September 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Any future regimen should satisfy the following principles. ^[1]

It should not have more than a maximum duration of 6 months
The dosing schedule must be simple
The number of drugs in it should be ideally not more than 3-5 drug each from a different class
It should have minimum side effect profile so that we could have minimum monitoring
It should be effective against MDR, XDR and XXDR strains
It should be administered per orally
It should have minimum interaction with anti retroviral drugs.
It should have atleast one new class of drug

@@ Line 24: / Line 24: @@
 ! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Drug}}
 ! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Phase}}
-! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|}}Class}}
+! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Class}}
 |-
 | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Moxifloxacin